Abstract: Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described.

Abstract: Methods of treating an individual exhibiting a medical condition are disclosed. The methods involve determining a score of an individual based on the individual's genotypic information, comparing the score to at least one threshold value, wherein the result of the comparison is indicative of a beneficial response to a treatment, and providing a suitable treatment to the individual.

Abstract: Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described.

Abstract: Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described.

Abstract: Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described.

Abstract: Multiple unique selection probes are provided in a single medium. Each selection probe has a sequence that is complementary to a unique target sequence that may be present in a sample under consideration. For example, each selection probe may be complementary to a sequence that includes one of the SNPs used to genotype an organism. Single-stranded selection probes anneal or hybridize with sample sequences having the unique target sequences specified by the selection probe sequences. Sequences from the sample that do not anneal or hybridize with the selection probes are separated from the bound sequences by an appropriate technique. The bound sequences can then be freed to provide a mixture of isolated target sequences, which can be used as needed for the application at hand.

Abstract: Methods of treating an individual exhibiting a medical condition are disclosed. The methods involve determining a score of an individual based on the individual's genotypic information, comparing the score to at least one threshold value, wherein the result of the comparison is indicative of a beneficial response to a treatment, and providing a suitable treatment to the individual.

Abstract: Improved life sciences business systems and methods are disclosed. One or more genomes are scanned for single nucleotide polymorphisms. The polymorphisms are used in association studies for pharmaceutical and diagnostic developments. In certain embodiments, an association study comprises both genotyping of these polymorphisms and resequencing of genomic regions that contain polymorphisms associated with a phenotypic state of interest.

Abstract: The invention provides a collection of polymorphic sites associated with response to treatment by an SSRI or placebo in depression patients. The polymorphic sites and others in linkage disequilibrium with them are useful in determining whether to treat a patient with an SSRI or include a patient in a clinical trial to test an SSRI.

Abstract: In one aspect, the invention provides a method of screening and, optionally, treatment of an individual suffering from an insulin resistance disorder by screening an individual in need of treatment for an insulin resistance disorder for one or more genetic variations indicating a predisposition to a response to an insulin sensitizer; and, optionally, administering or not administering an insulin sensitizer to the individual based on the results of the screening. The insulin sensitizer for which the individual is screened and the insulin sensitizer that is administered or not administered may be the same or different. In another aspect, the invention provides methods comprising identifying one or more genetic variations, e.g.

Abstract: Improved life sciences business systems and methods are disclosed. One or more genomes are scanned for single nucleotide polymorphisms. The polymorphisms are assigned to haplotype blocks, and representative SNPs from the haplotype blocks are used in association studies for pharmaceutical and diagnostic developments.

Abstract: Methods and devices are provided for using high-density arrays of diverse chemical entities. In preferred embodiments, small volumes of multiple liquids are delivered to multiple reaction sites on a single substrate where the liquids are constrained to localized reaction sites. The substrate need not be cut apart prior to being used for analysis. Accordingly, the area of the substrate on which analysis may be performed is maximized. In many embodiments of the present invention, constraining regions hinder the transport of liquids between adjacent reaction sites.

Abstract: Methods and systems for identifying biological marker-placebo effect correlations are provided. Clinical trial design and data analysis of clinical trial data is modified to accommodate marker-placebo effect correlations.

Abstract: The present invention relates to business methods for discovery of therapeutic and diagnostic products by identifying variations that occur in the human genome, relating these variations to one another, and, ultimately, relating these variations to the genetic bases of phenotype such as disease resistance, disease susceptibility or drug response.

Abstract: Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described.

Abstract: The invention provides a collection of polymorphic sites associated with variations in human skin color, and genes containing or proximal to the sites.

Abstract: Compositions and methods for use in the therapeutic and preventative treatment, study, diagnosis and prognosis of PD-related disease are disclosed. Also provided are kits and reagents for prognosis and diagnosis of PD-related disease and related conditions.

Abstract: Methods are described for assessing an individual's likelihood of developing or exhibiting a multifactorial trait, and for predicting the effectiveness of a drug treatment regimen in an individual. The methods include determining a plurality of genotypes for the individual at a plurality of biallelic polymorphic loci, using the genotypes to compute a score for the individual, and comparing the score to at least one threshold value. Genetic tests are also described for assessing an individual's likelihood of developing or exhibiting a multifactorial trait.

Abstract: Disclosed are techniques for reliably detecting target sequences in a complex nucleic acid sample, typically in the range of about 400 MB or greater, without employing a complexity reduction technique. The method employs relatively high quantities of a hybridization competitor, e.g., multiple times the amount of nucleic acid sample present. When the sample and competitor come in contact with nucleic acid probes complementary to target sequences, for an appropriate length of time under defined hybridization conditions (buffer composition, temperature, etc.), the target and probe hybridize reliably.

Abstract: Improved pharmaceutical and diagnostic business systems and methods are disclosed. One or more genomes are scanned for single nucleotide polymorphisms. The polymorphisms are assigned to haplotype blocks, and representative SNPs from the haplotype blocks are used in association studies for pharmaceutical and diagnostic development.